4.9. cystine stones. cystine stones account 1-2% urinary stones adults 6-8% stones reported paediatric studies . cystine stone formers deemed high risk recurrence ckd . 4.9.1. diagnosis blood analysis includes measurement creatinine, urinalysis includes measurement urine volume, ph profile, specific weight, cystine. since disease may asymptomatic, siblings cystinuric patients investigated cystinuria . interpretation cystine poorly soluble urine crystallises spontaneously within physiological urinary ph range.cystine solubility depends strongly urine ph: ph 6.0, limit solubility 1.33 mmol/l.routine analysis cystine suitable therapeutic monitoring.regardless phenotype genotype cystinuric patient, clinical manifestations .there role genotyping patients routine management cystinuria .reductive therapy targets disulphide binding cystine molecule. therapy monitoring, important differentiate cystine, cysteine, drug-cysteine complexes. however, available methods monitor cystinuria treatment may able differentiate different complexes formed therapy cumbersome non accurate, including high-performance liquid chromatography (hplc) .quantitative 24-hour urinary cystine excretion confirms diagnosis absence stone analysis.levels 0.125 mmol/day (30 mg/day) considered abnormal . 4.9.2. specific treatment general preventative measures fluid intake diet recommended. diet low methionine may theoretically reduce urinary excretion cystine; however, patients unlikely comply sufficiently diet. restricted intake sodium easily achieved effective reducing urinary cystine. patients usually advised avoid sodium consumption > 2 g/day (5 g nacl) . high level diuresis fundamental importance, aiming 24-hour urine volume > 3 l [683,690-692]. considerable fluid intake evenly distributed throughout day necessary. 4.9.2.1. pharmacological treatment cystine stones main therapeutic option avoiding cystine crystallisation maintain urine ph > 7.5, improve cysteine solubility, ensure appropriate hydration minimum >3 l/day adults, 1.5 l/m2 body surface area children [683,690-692]. home monitoring urine ph suggested possibility self-adjusting alkaline treatment keeping urine ph within range . free cystine concentration decreased reductive substances, act splitting disulphide binding cystine. tiopronin currently best choice cystine reduction. however, side effects often lead treatment termination, example nephrotic syndrome develops poor compliance, especially long-term use. carefully considering risk early tachyphylaxis, putting place dose-escape phenomenon long-term use, recurrence risk, tiopronin recommended cystine levels > 3.0 mmol/day (720 mg/day) case recurring stone formation, notwithstanding preventive measures [683,690-692]. spot measurement urine protein performed baseline follow-up. figure 4.9: metabolic management cystine stones 4.9.3. summary evidence recommendations management cystine stones summary evidenceleincreasing fluid intake 24-hour urine volume exceeds 3 l used dilute cystine.3alkaline citrates 3-10 mmol two three times daily used achieve ph > 7.5.3tiopronin, 250-2,000 mg/day used reduce stone formation patients cysteine excretion, > 3 mmol/day, measures insufficient.3 recommendationsstrength ratingtherapeutic measuresurine dilutionadvise patients increase fluid intake 24-hour urine volume exceeds 3 l.strongalkalinisationprescribe potassium citrate 3-10 mmol two three times daily, achieve ph > 7.5strongcomplex formation cystinefor patients cystine excretion, > 3 mmol/day, measures insufficient: prescribe addition measures tiopronin, 250-2,000 mg/day.strong